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Abstract
Purpose: To assess the efficacy of stereotactic body radiotherapy in patients with unresectable locally advanced pancreatic
cancer. Materials and Methods: All patients received a prescription dose of 45 Gy in 6 fractions. Primary end point was
freedom from local progression. Secondary end points were overall survival, progression-free survival, and toxicity. Actuarial
survival analysis and univariate or multivariate analysis were investigated. Results: Forty-five patients were enrolled in a phase 2
trial. Median follow-up was 13.5 months. Freedom from local progression was 90% at 2 years. On univariate (P < .03) and
multivariate analyses (P < .001), lesion size was statistically significant for freedom from local progression. Median progression-
free survival and overall survival were 8 and 13 months, respectively. On multivariate analysis, tumor size (P < .001) and freedom
from local progression (P < .002) were significantly correlated with overall survival. Thirty-two (71%) patients with locally
advanced pancreatic cancer received chemotherapy before stereotactic body radiotherapy. Median overall survival from diagnosis
was 19 months. Multivariate analysis showed that freedom from local progression (P < .035), tumor diameter (P < .002), and
computed tomography before stereotactic body radiotherapy (P < .001) were significantly correlated with overall survival from
diagnosis. Conclusion: Stereotactic body radiotherapy is a safe and effective treatment for patients with locally advanced
pancreatic cancer with no G3 toxicity or greater and could be a promising therapeutic option in multimodality treatment regimen.
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Introduction
Pancreatic ductal adenocarcinoma is characterized by a poor
prognosis, with a 5-year overall survival (OS) rate of about
6%.1,2 Surgery is the gold standard of care with 5-year OS rates
of 20% to 25%. More than 50% of patients, however, are unre-
sectable at the time of diagnosis, mainly due to locally
advanced disease or distant metastases.3 In patients with locally
advanced pancreatic cancer (LAPC), the integration of che-
motherapy and chemoradiation treatment (CRT) is the current
therapeutic option associated with a significant grade 3 to 4
toxicity rate and with a median OS of 5 to 15 months.4-8
In the last years, the feasibility and efficacy of stereotactic
body radiotherapy (SBRT) in the treatment of pancreatic can-
cer were investigated,9 but only few prospective trials have
been performed and several studies reported significant late
toxicity rates.10-23
The aim of this study was to investigate the efficacy and
safety of pancreatic SBRT with a total dose of 45 Gy in 6
fractions of 7.5 Gy/fraction.
Materials and Methods
Enrolment and Eligibility
Patients with histologically proven LAPC were enrolled in this
prospective, observational, single-arm, single-institution phase
2 trial, approved by the Humanitas Ethical Review Board. All
procedures performed were in accordance with the ethical stan-
dards of the institutional and/or national research committee
and with the 1964 Helsinki declaration and its later amend-
ments or comparable ethical standards. Informed consent was
obtained from all participants.
Primary end point was local control (LC) such as freedom
from local progression (FFLP). Secondary end points were OS,
progression-free survival (PFS), and toxicity rate.
Inclusion criteria were histologically proven unresectable
primary pancreatic adenocarcinoma, age18 years, Karnofsky
performance score of at least 70, lesions with maximum dia-
meter not exceeding 5 cm, negative lymph node, and absence
of distant metastasis. Exclusion criteria were previous abdom-
inal radiotherapy, nodal and/or metastatic disease, gastric or
duodenal obstruction, and concurrent chemotherapy.
All patients were evaluated by a medical oncologist, a bili-
ary–pancreatic surgeon, a radiologist, and a radiation oncolo-
gist in a multidisciplinary board.
Unresectable pancreatic cancer was defined according to
the American Hepato–Pancreato–Biliary Association/Society
of surgical Oncology/Society for Surgery of the Alimentary
Tract criteria24
Stereotactic Body Radiation
Patients were immobilized in supine position with the arms
above the head, using a thermoplastic body mask including a
Styrofoam block for abdominal compression to minimize inter-
nal organ motion (spontaneous or breath induced).
A contrast-free and venous phase contrast-enhanced com-
puted tomography (CT) scan with a slice thickness of 3 mm
was acquired for all patients. The clinical target volume (CTV),
defined as the gross tumor volume (GTV) with no additional
margins, was delineated on the venous phase of CT scan.
Eight patients had a positive staging [18F]fluorodeoxyglu-
cose-positron emission tomography (FDG-PET). In this sub-
population of patients, FDG-PET scan was acquired during the
simulation phase, and planning CT images were coregistered
(with deformable registration methods) with positron emission
tomography–computed tomography (PET-CT) to better iden-
tify the GTV.
In all 8 patients, no significant difference in the GTV defined
by PET and by venous contrast-enhanced CT was detected.
The planning target volume (PTV) was generated fromGTV
by adding a margin of 5 mm in the left–right direction, 5 mm in
the anterior–posterior direction, and 10 mm in the cranial–cau-
dal direction. Organs at risk (OARs), including the duodenum,
the stomach, the small bowel, the kidneys, the liver, and the
spinal cord, were contoured.
Stereotactic body radiotherapy plans were optimized and
delivered according to the RapidArc (Varian Medical Sys-
tems, Palo Alto, California) volumetric-modulated arc tech-
nique. Beam energy of 6 to 10 MV with flattened or
unflattened Flattening Filter Free (FFF) photon beams was
selected for all patients. Treatments were delivered by a True-
Beam linear accelerator (Varian Medical Systems).
A total dose of 45 Gy was given in 6 consecutive daily frac-
tions (7.5 Gy/fraction) with plan normalization to the mean dose
to CTV. Biologically equivalent dose was 78.8 and 157.5 Gy
using a/b ¼ 10 Gy for tumor and a/b ¼ 3 Gy for late gastro-
intestinal toxicity, respectively. The optimization of the dose
distribution was performed with the purpose of achieving the
following clinical goals. A required target coverage of V95% ¼
100% for the CTV. A maximum acceptable dose heterogeneity
to the CTV of D98% > 95% and D2% < 107%.
For PTV, the same objectives were ideally to be
achieved but with a lower priority than the constraints to
the OARs. The dose–volume constraints for the OARs
were duodenum D1cm3 < 36 Gy, stomach and small bowels
D3cm3 < 36 Gy, kidneys V15Gy < 35%, liver, total spared volume
(Vtot V21Gy, ) > 700 cm3, and spinal cord D1cm3 < 18 Gy.
Image guidance was performed by means of cone beam CT
imaging before every treatment session to verify the correct
position of the patient.
Response Evaluation and Follow-Up
Patients underwent clinical assessment at 1 month after SBRT
and then every 3 months thereafter by the treating radiation
oncologist. Clinical examination, evaluation of CA19-9 levels,
and a contrast-enhanced CT scan were performed at each step
of the follow-up. A PET-CT scan was also performed every 6
months after SBRT in those patients who had a pre-SBRT
staging PET-CT scan. Local control was defined according to
RECIST criteria.25 Acute and late toxicity was scored
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according to the National Cancer Institute (NCI) Common Ter-
minology Criteria for Adverse Events (CTCAE) v3.0.26
Statistical Analysis
Plan quality assessment was performed by means of numerical
analysis of the dose–volume histograms computed for each
organ/structure from the treatment plan. Several metrics were
computed and results will be reported for the dose–volume para-
meters used as objectives in the optimization. The conformity
index was defined as the ratio of the body volume irradiated at
95% of the prescription dose to the volume of the target (PTV).
From the clinical point of view, the primary end point of this
trial was to evaluate LC. Freedom from local progression was
calculated from the end of SBRT to the first assessment of local
progression. Patients who did not develop local disease pro-
gression were censored at the date of the last scan.
Secondary end points were PFS, OS, and toxicity.
Progression-free survival was calculated from the end of SBRT
to the first assessment of disease progression, and OS was
calculated from the end of SBRT to death.
Freedom from local progression, PFS, and OS rates were
calculated by Kaplan-Meier method, and the log-rank test sta-
tistic was used for univariate analysis to assess the level of
statistical significance between the strata of selected prognostic
factors. Cox regression provided a multivariate analysis of
these end points with selected prognostic factors. A significant
difference was considered when P  .05.
Results
Forty-five patients were enrolled from 2011 to 2013; 43 were
available for analysis (Figure 1). Patients and treatment char-
acteristics are shown in Table 1. Median CTV was 23.97 cm3
(range: 3.66-53.59 cm3) and median PTV was 64.73 cm3
(range: 21.3-127.4 cm3).
Thirty-two (71%) patients received pre-SBRT chemother-
apy, completed at least 2 weeks before SBRT. Table 2 presents
the results of the numerical analysis of the treatment plans from
a dose point of view. All planning objectives were respected
for both target coverage and OARs sparing with only 1 mild
violation in the duodenum for a patient receiving 36.5 Gy as
near-to-maximum dose instead of the objective of <36 Gy.
Conformity index resulted 1.11 + 0.21.
Median follow-up was 13.5 months (6-48 months). Eight
(18%) patients were alive at the time of analysis. Median
follow-up in this group was 23.5 months (range 11-48 months).
Thirty-two (71%) patients received pre-SBRT chemother-
apy, completed at least 2 weeks before SBRT. Chemotherapy
cycles ranged between 3 and 14. Nineteen percent of these
patients received a gemcitabine-based chemotherapy. The
variability of regimen and number of cycles of systemic ther-
apy were related to the PS, age, comorbidity, and compliance
of patients and to the chemotherapy-related toxicity. The
remaining 29% of the enrolled patients were not eligible to
CT for age, comorbidity, or performance status.
Three patients had an important tumor regression at about 3
months after SBRT and were treated with radical surgery.
These patients were excluded from the final analysis (Figure 1).
Twenty (48%) patients received CT at the time of local and/
or systemic disease progression after SBRT. Gemcitabine-
based chemotherapy was used in 14 patients, Fluorouracile-
Irinotecan (FOLFIRI) in 4 patients, and capecitabine in
2 patients. A total of 11 patients were not eligible to CT at the
time of disease progression for age or poor performance status.
Table 3 summarizes the results for FFLP, OS, and OS from
diagnosis (OSd).
The actuarial curve for FFLP is shown in Figure 2A. Local
progression occurred in 2 patients at 4 and 6 months and in 1
patient at 8 and 29 months. On univariate analysis, tumor dia-
meter (P < .03) was statistically significant for LC (Table 4).
Figure 1. Study schematics.
Table 1. Patients Characteristics.
Patients number 45
Mean age (range) years 68 (40-87)
Sex (M:F) 17:28
Primary site
Head 32 (72%)
Body/tail 13 (28%)
CA19-9 value pre-SBRT 28 (62%)
<300 U/mL 12 (43%)
>300 U/mL 16 (57%)
Not available 17 (38%)
Pre-SBRT chemotherapy 32 (71%)
GEMOX 17 (38%)
GEM 7 (1.5%)
PEF-G 6 (1%)
Altro 2 (<1%)
Post-SBRT chemotherapy 20 (48%)
GEM based 14 (70%)
FOLFIRI 4 (20%)
Capecitabine 2 (10%)
Median CTV (cm3) 23.97 (3.66-53.59)
Median CTV diameter (cm) 3.55 (1.8-4.7)
Median PTV (cm3) 64.73 (21.3-127.41)
Abbreviations: CTV clinical target volume; PTV, planning target volume;
SBRT, stereotactic body radiotherapy.
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One- and 2-year FFLP rates were 100% for patients with lesion
size <3.5 cm and 76% for lesion size >3.5 cm (Figure 2B).
Actuarial OS is shown in Figure 2C; median OS was calcu-
lated from the end of SBRT. Eight (18%) patients were alive at
the time of analysis, with a median OS of 23.5 months. On
multivariate analysis, tumor size (P < .001) and FFLP
(P < .002) were significantly correlated with OS (Table 4).
The actuarial curve for the OSd is shown in Figure 2C. On
univariate analysis, CT before SBRT (P < .015) was signifi-
cantly associated with OSd (Table 4). Median OSd was 23.93
months in those patients treated with CT and sequential SBRT
and 15 months in those patients treated with only SBRT (Figure
2E). On multivariate analysis, FFLP (P < 0.035), tumor dia-
meter (P < .002), and CT before SBRT (P < .001) were signif-
icantly correlated with OSd.
Figure 3 represents a typical treatment and a clinical response
after SBRT. In the figure, the contour is the CTV that is reported
together with the dose (in color wash ranging from 95% to 107%
of the dose prescription to enhance the appraisal of the dose
conformity, the PTV contour falls at the edge of the color wash).
The follow-up image was acquired 6 months after treatment.
Twenty-one (49%) patients experienced mild or moderate
acute toxicity (grade 1 or 2): 4 (10%) nausea, 16 (37%) fatigue,
and 1 (2%) abdominal pain. No case of acute toxicityG3 was
detected. Only 2 patients (4%) experienced late toxicity. These
patients developed G2 gastritis after more than 3 months from
SBRT, and they were treated with proton pump inhibitor (PPI).
No late toxicity G3 was experienced.
According to the Numerical Rating Scale scoring system, 17
(39%) patients experienced pain before SBRT. In 10 (62%)
patients, pain control after treatment allowed suspension of
analgesics administration; in 5 (28%) patients, analgesics
dosage was reduced by 50%; and in 2 (10%) patients, admin-
istration was reduced by 20%.
Discussion
In the past years, the role of SBRT in the treatment of unresect-
able pancreatic cancer was investigated to confirm the hypothe-
tical advantages of this therapy over conventional CRT.
As shown by Brunner et al,9 higher LC related to the high
doses used, short overall treatment time, and sequential inte-
gration with systemic therapy represent the crucial advantages
of SBRT, but the dose-related gastrointestinal toxicity is still a
serious open issue (Table 5).
Most of the published studies, indeed, demonstrated that
acute toxicity was generally mild, but late toxicity was signif-
icant, with rates up to 18% to 47%.12,13 Results of this phase 2
trial demonstrated that SBRT represents a significant and safe
therapeutic option for patients with unresectable LAPC. Frac-
tionation adopted in our study, indeed, was associated with a
satisfactory LC rate, particularly for small lesions, with a very
low toxicity profile. A promising OS rates were achieved
almost in patients with LAPC and a low pre-SBRT CA19-9
value and in patients treated with CT before SBRT. In our
study, indeed, no patients experienced perforation, ulcer,
bleeding, or other acute or late grade 3 toxicity or higher. Only
2 patients experienced grade 2 late gastritis, confirming the
safety of our SBRT regimen. We feel that this optimal toxicity
profile is due to the crucial factors: our immobilization system
that minimizes the internal organ motion, reducing the dose to
OARs and the high conformity of dose, and the priority to
duodenal, stomach, and bowel dose constraints. That is to limit
the maximum dose to 36 Gy. Prospective studies on the effi-
cacy of SBRT in patients with unresectable pancreatic cancer
showed a 1-year LC rate ranging from 40% to 95% (Table 5).
Satisfying results in terms of FFLP are reported in 4 phase 1
and 2 trials: 3 studies from Stanford University11,13-15 using a
single fraction (25 Gy) and 1 from Baltimore group17 using 3
fractions (15-30 Gy), with 1-year FFLP rate of about 92% to
100%. Reported rates of late duodenal ulceration, however,
were significant (20%-47%). In 2014, the same group from
Stanford University published a prospective study on SBRT
in 5 fractions (33 Gy), with a decreasing late toxicity rate and
1-year FFLP rate of 78%. In our trial, fractionation of 45 Gy in
6 fractions allowed to achieve encouraging 1-year FFLP rates
for LAPC with a very low toxicity profile. The correlation
between FFLP and tumor diameter at univariate and multivari-
ate analyses suggested the importance of dose escalation in
patients with large lesions. As shown in our previous pilot
Table 2. Summary of Planning Dose–Volume Objectives.a
Structure/
Organ Dose–Volume Objective DVH Analysis
CTV V95% ¼ 100% (%) 100.0+ 0.0
D98% > 95% (Gy) 98.0+ 1.8 [94.0-99.9]
D2% < 107% (Gy) 0.0+ 0.0
PTV D95% > 95% (Gy) 96.8+ 1.8 [94.9-99.9]
D2% < 107% (Gy) 0.3+ 1.3 [0.0-4.3]
Duodenum D1cm3 < 36 Gy(Gy) 31.2+ 5.0 [20.8-36.5]
Stomach D3cm3 < 36 Gy(Gy) 14.5+ 12.3 [0.3-35.3]
Small bowels D3cm3 < 36 Gy(Gy) 28.7+ 6.6 [15.3-38.4]
Kidneys V15Gy < 35% (%) Left: 1.8+ 6.8 [0.0-33.7]
Right: 1.4+3.1 [0.0-10.9]
Spinal cord D3cm3 < 18 Gy (Gy) 8.5+ 3.0 [3.5-14.9]
Liver Vtot  V21Gy >
700 cm3(cm3)
1306 + 54 [987-1494]
Abbreviations: CTV, clinical target volume, DVH, dose–volume histogram;
PTV, planning target volume.
aResults are reported as mean and standard deviation. Values inside the square
brackets represent the range.
Table 3. Summary of the Actuarial Analysis for FFLP, PFS, OS, and
Osd.
Median 1 year 2 years
FFLP 26 months, 95% CI: 23-29 87% + 6% 87%+ 6%
PFS 8 months, 95% CI: 4.8-11.2 39% + 8% 15%+ 9%
OS 13 months, 95% CI: 10.5-15.5 59% + 7% 18%+ 9%
OSd 19 months, 95% CI: 17.2-20.8 85% + 5% 33%+ 7%
Abbreviations: CI, confidence interval; FFLP, freedom from local progression;
OS, overall survival; OSd, overall survival from diagnosis; PFS, progression-
free survival.
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study21 and recently confirmed by Brunner et al, LC seems to
be correlated with higher prescription dose.9
In our experience, the importance of LC in patients with
pancreatic cancer treated with SBRT is confirmed by signifi-
cant correlation between FFLP and OS.
In most of the prospective published studies on SBRT for
LAPC, median OS ranged from 5.7 to 19months (Table 2). Better
results were achieved when SBRT was performed after
chemotherapy, with a median OS ranging from 10.3 to 20
months.13,15-16,19-23 These data could be related not only to the
efficacy of systemic therapy but also to the selection of patients
with a genetic tendency to local progression, during the timeofCT.
In our phase 2 trial, median OS calculated from the end of
SBRT was 13 months. As previously shown, tumor size and LC
were significant prognostic factors, although the use of CT
before SBRT was closely (P ¼ .071) but nonsignificantly cor-
related with OS.
When calculated from diagnosis, median OS was 19
months. Most of the patients (71%), indeed, were suitable for
sequential CT, administered before SBRT. Median OSd
improved significantly not only in those cases with small
lesions and optimal LC but also in patients pretreated with
CT. In this setting of patients, median OSd was about 2 years.
These results may confirm the importance of sequential inte-
gration of chemotherapy and SBRT in the treatment of LAPC.9
A several number of elderly patients or unfit or with important
comorbidity, however, are not suitable for chemotherapy. In
our experience, even though 29% of enrolled patients with
LAPC were not eligible to CT for age, comorbidity, or perfor-
mance status, outcome after only SBRT was encouraging, with
median OSd of 15 months. These data suggest that SBRT may
be a viable alternative treatment also in patients with poor
performance status, thanks also to low toxicity.
Conclusion
Freedom from local progression and OS in patients with unre-
sectable locally advanced pancreatic adenocarcinoma seem to
be improved by SBRT. Our results suggest that SBRT can be
considered an effective and safe therapeutic option in the multi-
modality treatment of this disease.
Figure 2. Actuarial survival curves of (A) freedom from local progression (FFLP); (B) FFLP for smaller and larger lesions; (C) progression-free
survival; (D) overall survival; (E) overall survival from diagnosis (OSd); and (F) overall survival for patients who received (not received)
chemotherapy before stereotactic body radiotherapy (SBRT).
Table 4. Results of Univariate and Multivariate Analysis (P values).
Factor affecting FFLP and OS
Univariate
Analysis
Multivariate
Analysis
FFLP OS FFLP OS OSd
Tumor diameter .03 .32 .001 .001 .002
CT before SBRT .81 .12 .842 .071 .001
Local control – 0.48 – .002 .035
Abbreviations: CT, computed tomography; FFLP, freedom from local progres-
sion; OS, overall survival; OSd, OSd, overall survival from diagnosis; SBRT,
stereotactic body radiotherapy.
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Figure 3. A typical example of treatment: (A) target volume before stereotactic body radiotherapy (SBRT); (B) dose distribution; (C) treatment
response at 6 months after treatment during follow-up. Dose distribution is shown with color wash set at 95% to 107% of the prescription dose.
The clinical target volume (CTV) contour is shown in the center of the dose distribution, and the planning target volume (PTV) contour is at the
edge of the color wash.
Table 5. Summary of treatment regimen, LC, PFS, OS, and late toxicity in recent study.
Author, Study,
Year (Reference) Patients (n)
SBRT Dose
(Gy/fraction)
1-year
FFLP (%)
PFS,
months OS, months
Acute GI
toxicity (>G2)
Late GI
toxicity ( G2)
Koong et al, Stanford
phase I, 200410
15 15-20 Gy/1 fr 77% 2 11 from diagnosis 33% –
Koong et al, Stanford
phase II, 200511
19 25 Gy/1 fr 94% 4 8 12.5% –
Hoyer et al, Danish phase
II, 200512
22 45 Gy/3 fr 57% 4.8 5.7 from diagnosis 79% 94%
Schellenberg et al,
Stanford 200813
16 25 Gy/1 fr 100% 9 11.4 from diagnosis 19% 47%
Chang et al, Stanford
200914
77 25 Gy/1 fr 84% – 11.4 from diagnosis 5% 13%
Schellenberg et al,
Stanford phase II
201115
20 25 Gy/1 fr 94% 9.2 11.8 from diagnosis 15% 20%
Polistina et al, Vicenza
201016
33 30 Gy/3 fr 82.6% 7.3 10.6 0 –
Didolkar et al, Baltimore
201017
85 15-30 Gy/3 fr 91.7% – 18.6 from diagnosis;
8.6 from SBRT
0 22%
Mahadevan et al,
Deaconess 201118
39 24-36 Gy/3 fr 85% 15 20 41% 6%
Rwigema et al, Pittsburgh
201119
71 18-25 Gy/1 fr 64.8% – 10.3 0 10%
Gurka et al, 201320 10 25 Gy/5 fr 40% – 12.2 0 0%
Tozzi et al, Milano 201321 30 36-45 Gy/6 fr 85% 8 11 from SBRT; 19.5 from
diagnosis
20% 0%
Chuong et al, 201322 16 25-50 Gy/5 fr 81% – 15 0% 5.3%
Herman et al, phase II
201523
49 33 Gy/5 fr 78% 7.8 13.9 12.2% 10.6%
Current study 45 45 Gy/6 fr LAPC: 90% LAPC: 8 LAPC: 13 from SBRT and
19 from diagnosis
29% 3%
Abbreviations: FFLP, freedom from local progression; fr, fraction; GI, gastrointestinal toxicity; LAPC, locally advanced pancreatic cancer; OS, overall survival;
PFS, progression-free survival; SBRT, stereotactic body radiotherapy.
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Future studies and trials are needed to evaluate the escala-
tion dose and the best integration with systemic therapy to
improve the outcomes of these patients in terms of LC and OS.
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